The extracorporeal treatment of septic patients: Is there an extrarenal indication?;Die Extrakorporale Therapie Septischer Patienten : Gibt es eine Extrarenale Indikation?

Intensivmedizin und Notfallmedizin

Volumn 44, Issue 2, 2007, Pages 57-63

  Schefold, J C ^a   Hasper, D ^a   Storm, C ^a   Corsepius, M ^a   Pschowski, R ^a   Reinke, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Extracorporeal treatment; Immunity; Inflammation; Macrophages; Sepsis

Indexed keywords

EID: 33947365998     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00390-007-0758-x     Document Type: Article

References (66)

1. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150
2. Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365:63-78
3. Dellinger RP, Carlet JM, Gerlach H et al (2004) The surviving sepsis guidelines: not another "groundhog day". Grit Care Med 32:1601-1602
4. Levy MM, Pronovost PJ, Dellinger RP et al (2004) Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome. Crit Care Med 32:8595-S597
5. Dellinger RP, Carlet JM, Masur H et al (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Grit Care Med 32:858-873
6. Levy MM, Fink MP, Marshall JC et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31: 1250-1256
7. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420:885-891
8. Volk HD, Reinke P, Docke WD (2000) Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol 74:162-177
9. Docke WD, Randow F, Syrbe U et al (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678-681
10. Docke WD, Hoflich C, Davis KA et al (2005) Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter study. Clin Chem
11. Hoflich C, Volk HD (2002) Immunomodulation in sepsis. Chirurg 73: 1100-1104
12. Dremsizov TT, Kellum JA, Angus DC (2004) Incidence and definition of sepsis and associated organ dysfunction. Int J Artif Organs 27:352-359
13. Kellum JA, Angus DC (2002) Patients are dying of acute renal failure. Crit Care Med 30:2156-2157
14. Druml W (2004) Acute renal failure is not a "cute" renal failure! Intensive Care Med 30:1886-1890
15. Gormley SM, McBride WT, Arm-strong MA et al (2002) Plasma and urinary cytokine homeostasis and renal function during cardiac surgery without cardiopulmonary bypass. Cytokine 17:61-65
16. Gotloib L, Barzilay E, Shustak A et al (1986) Hemofiltration in septic ARDS. The artificial kidney as an artificial endocrine lung. Resuscitation 13:123-132
17. Stein B, Pfenninger E, Grunert A et al (1990) Influence of continuous haemofiltration on haemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 16:494-499
18. Grootendorst AF, van Bommel EF, van der HB et al (1992) High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 18:235-240
19. Bellomo R, Honore PM, Matson J et al (2005) Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis. Int J Artif Organs 28:450-458
20. Carcillo JA, Kellum JA (2002) Is there a role for plasmapheresis/plasma exchange therapy in septic shock, MODS, and thrombocytopenia-associated multiple organ failure? We still do not know - but perhaps we are closer. Intensive Care Med 28:1373-1375
21. Kellum JA, Bellomo R, Mehta R et al (2003) Blood purification in non-renal critical illness. Blood Purif 21:6-13
22. McMaster P, Shann F (2003) The use of extracorporeal techniques to remove humoral factors in sepsis. Pediatr Crit Care Med 4:2-7
23. Ronco C, Inguaggiato P, D'Intini V et al (2003) The role of extracorporeal therapies in sepsis. J Nephrol 16 (Suppl 7):S34-S41
24. Ronco C, Bonello M, Bordoni V et al (2004) Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 22:164-174
25. Tetta C, D'Intini V, Bellomo R et al (2003) Extracorporeal treatments in sepsis: are there new perspectives? Clin Nephrol 60:299-304
26. Venkataraman R, Subramanian S, Kellum JA (2003) Clinical review: extracorporeal blood purification in severe sepsis. Crit Care 7:139-145
27. Kellum JA, Mehta RL, Angus DC et al (2002) The first international consensus conference on continuous renal replacement therapy. Kidney Int 62:1855-1863
28. Kellum JA, Angus DC, Johnson JP et al (2002) Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 28: 29-37
29. Ronco C, Bellomo R, Kellum JA (2002) Continuous renal replacement therapy: opinions and evidence. Adv Ren Replace Ther 9:229-244
30. Davenport A, Will EJ, Davidson AM (1993) Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 21:328-338
31. De Vriese AS, Vanholder RC, Pascual M et al (1999) Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med 25:903-910
32. De Vriese AS, Colardyn FA, Philippe JJ et al (1999) Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 10: 846-853
33. Bellomo R, Boyce N (1993) Continuous venovenous hemodiafiltration compared with conventional dialysis in critically ill patients with acute renal failure. ASAIO J 39:M794-M797
34. Bellomo R, Tipping P, Boyce N (1993) Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 21:522-526
35. Heering P, Morgera S, Schmilz FJ et al (1997) Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 23:288-296
36. Kellum JA, Johnson JP, Kramer D et al (1998) Diffusive vs convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med 26:1995-2000
37. Cole L, Bellomo R, Hart G et al (2002) A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 30:100-106
38. Schetz M (1994) Removal of cytokines in septic patients using continuous veno-venous hemodiafiltration. Crit Care Med 22:715-716
39. Kellum JA, Mehta RL, Angus DC et al (2002) The first international consensus conference on continuous renal replacement therapy. Kidney Int 62: 1855-1863
40. Honore PM, Joannes-Boyau O (2004) High volume hemofiltration (HVHF) in sepsis: a comprehensive review of rationale, clinical applicability, potential indications and recommendations for future research. Int J Artif Organs 27:1077-1082
41. Ronco C, Bellomo R, Homel P et al (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26-30
42. Kellum JA, Dishart MK (2002) Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats. Crit Care 6:429-433
43. Cole L, Bellomo R, Journois D et al (2001) High-volume haemofiltration in human septic shock. Intensive Care Med 27:978-986
44. Honore PM, Jamez J, Wauthier M et al (2000) Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 28:3581-3587
45. Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI et al (1999) Out-come of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis. Intensive Care Med 25:814-821
46. Ratanarat R, Brendolan A, Piccinni P et al (2005) Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care 9:R294-R302
47. Brendolan A, D'Intini V, Ricci Z et al (2004) Pulse high volume hemofiltration. Int J Artif Organs 27:398-403
48. Reiter K, Bellomo R, Ronco C et al (2002) Pro/con clinical debate: is high-volume hemofiltration beneficial in the treatment of septic shock? Crit Care 6:18-21
49. Lonnemann G, Bechstein M, Linnenweber S et al (1999) Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int (Suppl):S84-S87
50. Ronco C, Bellomo R, Hensel M (1997) Continuous "high flux" dialysis: an effective renal replacement therapy for intensive care patients. Zentralbl Chir 122:378-382
51. Tetta C, Cavaillon JM, Schulze M et al (1998) Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption. Nephrol Dial Transplant 13:1458-1464
52. Tetta C, Gianotti L, Cavaillon JM et al (2000) Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 28:1526-1533
53. Bosch T (2003) Recent advances in therapeutic apheresis. J Artif Organs 6:1-8
54. Palmer JD, Rifkind D (1974) Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg Gynecol Obstet 138:755-759
55. Yonekawa M (2005) Cytokine and endotoxin removal in critically 111 patients. Ther Apher Dial 9:A37
56. Uriu K, Osajima A, Hiroshige K et al (2002) Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am J Kidney Dis 39: 937-947
57. Vincent JL, Laterre PF, Cohen J et al (2005) A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400-405
58. Reinhart K, Meier-Hellmann A, Beale R et al (2004) Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gramnegative sepsis. Grit Care Med 32: 1662-1668
59. Bengsch S, Boos KS, Nagel D et al (2005) Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 23:494-500
60. Amoureux MC, Rajapakse N, Hegyi E et al (2004) Endotoxin removal from whole blood by a novel adsorption resin: efficiency and hemocompatibility. Int J Artif Organs 27:480-487
61. Staubach KH, Boehme M, Zimmermann M et al (2003) A new endotoxin adsorption device in Gram-negative sepsis: use of immobilized albumin with the MATISSE adsorber. Transfus Apher Sci 29:93-98
62. Schefold JC, von Haehling S, Corsepius M et al (2007) A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin-6, and complement-activating product 5a. Shock, in press
63. Leese T, Holliday M, Heath D et al (1987) Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Br J Surg 74:907-911
64. Busund R, Koukline V, Utrobin U et al (2002) Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 28:1434-1439
65. Schmidt J, Mann S, Mohr VD et al (2000) Plasmapheresis combined with continuous venovenous hemofiltration in surgical patients with sepsis. Intensive Care Med 26:532-537
66. Kellum JA, Song M, Venkataraman R (2004) Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 32:801-805